These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35274878)

  • 21. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
    Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
    J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
    [No Abstract]   [Full Text] [Related]  

  • 22. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis.
    Napolitano M; Gallo L; Megna M; Fabbrocini G; Nocerino M; Abategiovanni L; Patruno C
    Dermatol Ther; 2019 May; 32(3):e12900. PubMed ID: 30964566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute exacerbation of rheumatoid interstitial lung disease during the maintenance therapy with certolizumab pegol.
    Migita K; Tsuji Y; Hisatomi K; Shigeno R; Izumi Y; Iwanaga N; Koga T
    Mod Rheumatol; 2017 Nov; 27(6):1079-1082. PubMed ID: 26044288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
    Dhillon S
    Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
    Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary Cutaneous Nocardiosis in a Man Treated With Certolizumab.
    Gil Redondo R; Melgar Molero V; Martín Fuentes A; de Eusebio Murillo E
    Actas Dermosifiliogr (Engl Ed); 2019 Oct; 110(8):698-699. PubMed ID: 31133295
    [No Abstract]   [Full Text] [Related]  

  • 32. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
    Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
    BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
    Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
    J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
    Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
    Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Certolizumab pegol was effective for treating residual synovitis after total knee arthroplasty in a patient with rheumatoid arthritis: therapeutic monitoring by ultrasound.
    Kawashiri SY; Michitsuji T; Kawakami A
    J Med Ultrason (2001); 2018 Apr; 45(2):371-374. PubMed ID: 28725981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
    Pope J; Rampakakis E; Vaillancourt J; Bessette L; Lazovskis J; Haraoui B; Sampalis JS
    Rheumatology (Oxford); 2020 Jul; 59(7):1522-1528. PubMed ID: 31628486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Miller Fisher syndrome following treatment with certolizumab in a patient with rheumatoid arthritis].
    Alberola-Amores FJ; Navarro-Canto L; Gonzalez-Ferrandez JA
    Rev Neurol; 2017 Sep; 65(6):286-288. PubMed ID: 28896005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab.
    Hwang SR; Sawatsky AP
    J Rheumatol; 2019 Dec; 46(12):1647. PubMed ID: 31676702
    [No Abstract]   [Full Text] [Related]  

  • 39. Cutaneous leishmaniasis mimicking dactylitis in a patient with rheumatoid arthritis treated with certolizumab.
    Herrerias-Moreno J; Expósito-Serrano V; Agut-Busquet E; Corbacho M; Sáez E; Luelmo J
    Clin Exp Dermatol; 2018 Apr; 43(3):348-350. PubMed ID: 29218754
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports.
    Grossi V; Infantino M; Manfredi M; Basile U; Gulli F; Marino M; Li Gobbi F; Damiani A; Atzeni F; Benucci M
    Clin Chem Lab Med; 2020 Mar; 58(4):e105-e108. PubMed ID: 31665114
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.